Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Serono Onercept Psoriasis Studies Discontinued Due To Safety Concerns

This article was originally published in The Pink Sheet Daily

Executive Summary

Serono is discontinuing development of its anti-tumor necrosis factor agent onercept for moderate-to-severe psoriasis based on cases of sepsis reported during Phase III trials, the company said April 6

You may also be interested in...

Canvaxin Melanoma Vaccine BLA Delayed Until 2007 After Trial Fails

Serono/CancerVax data safety monitoring board recommends halting Phase III development of Canvaxin for Stage IV melanoma due to lack of efficacy. Pivotal program for Stage III disease continues; no safety issues were identified with either study.

US FDA Expands Drug Development Tool Qualification Program With ISTAND Pilot

ClinROs, artificial intelligence-based algorithms will be included in approval pathway. FDA is taking a crash course on new techniques for trial assessment thanks to COVID.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts